CLCZ696B2319E1 open-label extension (OLE) study to evaluate long-term safety and tolerability of sacubitril/valsartan in pediatric patients with heart failure

Phase 3

Completed

• Conditions: Pediatric Heart Failure

• Registration Number: JPRN-jRCT2080224897
• Lead Sponsor: ovartis Pharma. K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

On study drug at PANORAMA-HF Part 2 EOS visit. Does not have any significant safety issue

Exclusion Criteria

- On study drug at PANORAMA-HF Part 2 EOS visit. Does not have any significant safety issue
- Renal vascular hypertension (including renal artery stenosis)
- Significant renal estimated glomerular filtration rate disorder, hepatic disorder, gastrointestinal disorder or biliary disorder
- History of angioedema

Study & Design

• Study Type: Interventional
• Study Design: Not specified